Section of Cardiology, Department of Medicine, Baylor College of Medicine, 2002 Holcombe Blvd, Houston, TX, 77030, USA.
Department of Medicine, Division of Cardiology, Duke University School of Medicine, Raleigh, NC, USA.
Curr Atheroscler Rep. 2022 Aug;24(8):627-634. doi: 10.1007/s11883-022-01038-2. Epub 2022 Jun 2.
In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes.
Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms. SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.
在本次综述中，我们讨论了钠-葡萄糖协同转运蛋白 2 抑制剂（SGLT-2i）的作用机制，以及其减轻心力衰竭（HF）相关结局的潜在保护作用。
大型随机临床试验已经证实了 SGLT-2i 在无已知 HF 患者以及射血分数降低或保留的 HF（分别为 HFrEF 和 HFpEF）患者中的心血管安全性和疗效。最近的 HF 指南已将 SGLT-2i 纳入 HF 治疗算法。SGLT-2i 已成为预防 HF 以及降低现有 HFrEF 或 HFpEF 患者心血管发病率和死亡率的一种新疗法。
